drugset / Trial / NCT06613035
Twice-per-weekSelinexor, 2 Days Melphalan
RandomizedParallel-groupOpen-labelTreatment
Summary
Twice-per-week Selinexor, 2 days Melphalan plus BU2FLU3 compared with BU3FLU5 for elder high-risk acute myeloid leukemia undergoing allogenic hematopoietic cell transplantation: a multi-center randomized phase 3 trial
Timeline
- Start
- 2024-09-30
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Melphalan | Small molecule | 60 mg/m2 | — |
| Subject | Selinexor | Other / unclassified | 60 mg | — |